Bio-Rad Laboratories, a specialist in life science research and clinical diagnostic products, has extended its range of recombinant monoclonal anti-idiotypic antibodies with the introduction of antibodies that are specific for ipilimumab (Yervoy) and the ipilimumab/CTLA-4 drug-target complex. These highly specific and high-affinity antibodies are suitable for bioanalytical and patient drug level monitoring assays for the immune checkpoint inhibitor: ipilimumab.
Bio-Rad also announced the launch of a range of anti-certolizumab pegol inhibitory antibodies to support the development of assays for therapeutic drug monitoring of tumor necrosis factor (TNF) alpha inhibitors.
Ipilimumab activates the immune system by inhibiting cytotoxic T lymphocyte-associated antigen 4 (CTLA-4), a protein receptor that hinders the destruction of cancerous cells, to treat cancers such as melanoma. The four anti-ipilimumab antibodies inhibit the binding of the drug to its target, CTLA-4, and therefore detect free drug. These antibodies are suitable for developing pharmacokinetic (PK) bridging ELISAs and being used as a surrogate positive control (or reference standard) for anti-drug antibody assays. The drug-target complex binder specifically recognizes the ipilimumab/CTLA-4 complex and can be used as the detection antibody in a PK antigen capture assay as an alternative format to the bridging ELISA.
The recombinant monoclonal anti-idiotypic antibodies are generated using the Human Combinatorial Antibody Library (HuCAL®) and CysDisplay®, a proprietary method of phage display with guided selection methods to obtain highly targeted reagents. The recombinant production method also ensures a consistent and secure supply.
The anti-ipilimumab antibodies are approved for in vitro research and for commercial applications of in vitro testing services that support preclinical and clinical drug and biosimilar development and patient monitoring.
Anti-certolizumab pegol inhibitory antibodies
The range of recombinant monoclonal anti-idiotypic antibodies comprises three antibodies that are highly specific for the monoclonal antibody Fab fragment certolizumab pegol (Cimzia) and inhibit the binding of this drug to its target: TNF alpha. The antibodies are fully human in full length IgG format and can be used as a surrogate positive control or calibration standard for an ADA assay to measure levels of patient anti-drug antibodies.
TNF alpha inhibitors are used to treat a wide range of inflammatory conditions such as rheumatoid arthritis, Crohn’s disease, and psoriasis. The levels of serum drug and ADA concentrations are monitored in patients receiving TNF alpha antagonists to help guide clinical decision making, optimize treatment, improve outcomes, and reduce healthcare costs.
The anti-certolizumab pegol antibodies are approved for in vitro research and for commercial applications of in vitro testing services that support preclinical and clinical drug and biosimilar development and patient monitoring.
Read more

DOAC Stop eliminates all direct oral anti-coagulants (DOACs) from test plasmas, making it possible to obtain valid results for all conventional coagulation assays and tests for thrombophilia.  This adsorbent has amazing affinity for DOACs but no effect on clotting proteins, antibodies or heparins. Because it extracts only DOACs, a clotting test result which remains abnormal can be assumed to have other causes.  DOAC Stop minitabs (one/ml) disperse readily in plasma and take less than 5 minutes to bind more than 95% of DOACs in most cases. The adsorbent is quickly removable after it has done its work by centrifugation.  The minitabs work equally well on direct thrombin inhibitors (eg dabigatran) and those against FXa (rivaroxaban, apixaban, edoxaban) and have no effect on heparins or warfarin plasmas.  In most cases DOAC levels can be estimated quickly from the ratio of clotting test results before to after the extraction via an appropriate calibration curve. The best results are obtainable using high phospholipid dRVVT or APTT reagents.

HAEMATEX
Read more

Shimadzu’s iMLayer boosts spatial resolution for MS imaging experiments. It enables reproducible matrix coating with small crystals and minimizes delocalization effects. Get a crystal clear view of microstructures in your sample.
Features

• Creation of fine matrix crystals by unique matrix vapor deposition technology (sublimation) enabling high resolution MS imaging experiments
• Minimized delocalization effects compared to conventional spraying method due to sublimation technique
• Good reproducibility through automated matrix layer thickness control
• Simple touch pad operation making the easy-to-use standalone instrument a sample preparation tool for any MS imaging experiment

For information please click here.
Read more

Logan, UT, January 17, 2020 – ELITechGroup Inc., recognized worldwide as slide staining and cytocentrifuge technologic pioneers and innovators, with nearly 30 patents, over the 35-year lifespan of Aerospray staining technology, announces the launch of the Aerospray Cytology Slide Stainer Cytocentrifuge. The ELITechGroup’s Aerospray Cytology Slide Stainer/Cytocentrifuge automates the preparation and staining of liquid based cytology specimens to facilitate the examination of an array of cell differentiations utilizing Papanicolaou staining techniques. The advantages of the Aerospray Cytology Slide Stainer/Cytocentrifuge is that the device performs two functions of sample preparation through cytocentrifugation and sample staining. The system maximizes cell recovery to the slide through the use of its Cytopro® Rotor, eliminates cross-contamination with an application of fresh stain for each slide, and provides programmable regressive and progressive staining capabilities that can be stored in memory to meet the needs and preferences of any end user. The instrument standardizes staining across multiple labs, provides consistently high-quality control, is low maintenance, reduces the labor/cost per slide, enables laboratory compliance, and is the perfect back-up for high automation laboratories for specialty staining and during maintenance. “ELITechGroup’s portfolio of Aerospray slide stainers and cytocentrifuges has enabled the company to develop a worldwide reputation for performance and reliability. Our new Aerospray Cytology Stainer/Cytocentrifuge proves our commitment to ongoing innovation by expanding into new laboratories where we can offer superior staining results,” says Bryce McEuen, Vice President, Biomedical Systems. ELITechGroup will be showcasing the Aerospray Cytology Slide Stainer/Cytocentrifuge at key industry events throughout the year of 2020. Learn more at AerosprayStaining.com.
About ELITechGroup
ELITechGroup is a privately held group of worldwide manufacturers and distributors of in vitro diagnostic equipment and reagents for clinical systems, microbiology, molecular diagnostics, hematology, cytology, and sweat test systems. Their mission is to improve patient care by empowering laboratories to do more in less time, with accuracy, to enable rapid and accurate course of treatment for patients.
Read more

TRIMERO offers C1q, C5, C1 (Esterase) Inhibitor and Factor B (C3 Proactivator) CE- marked assays for nephelometry and turbidimetry.
Assays are available for IMMAGE^® immunochemical systems of Beckman Coulter and for BN™ Series nephelometers of Siemens Healthineers.
Turbidimetric assays and applications are also available for the most popular clinical chemistry analysers.
In order to ensure lot to lot traceability, values ​​have been referred to the International Ref. Preparation for human serum complement Factors (NIBSC code: W1032) of the WHO (World Health Organization). 
Other available assays for nephelometry and turbidimetry include:
KLoneus^® Free Light Chains (FLC), Serum Amyloid A (SAA), IgD Immunoglobulins, Retinol Binding Protein (RBP) for serum and urine, Soluble Transferrin Receptor (sTfR), Hemopexin, Cystatin-C for serum and urine, A1-Microglobulin, B2-Microglobulin for serum and urine, Kappa and Lambda Light Chains for serum and urine.
Read more